Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels

NCT01678313 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

140

Enrollment

OTHER

Sponsor class

Conditions

Benign Prostatic Hyperplasia

Interventions

DRUG: Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD)
DRUG: Doxazosin 4 mg every day (QD)

Sponsor

Buddhist Tzu Chi General Hospital